Inflation using hydrogen improves donor lung quality by regulating mitochondrial function during cold ischemia phase.
Cold ischemia
Donor lung quality
Hydrogen
Inflammation
Lung transplantation
Mitochondrial function
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
17 Jun 2023
17 Jun 2023
Historique:
received:
28
11
2022
accepted:
31
05
2023
medline:
19
6
2023
pubmed:
18
6
2023
entrez:
17
6
2023
Statut:
epublish
Résumé
Mitochondrial dysfunction results in poor organ quality, negatively affecting the outcomes of lung transplantation. Whether hydrogen benefits mitochondrial function in cold-preserved donors remain unclear. The present study assessed the effect of hydrogen on mitochondrial dysfunction in donor lung injury during cold ischemia phase (CIP) and explored the underlying regulatory mechanism. Left donor lungs were inflated using 40% oxygen + 60% nitrogen (O group), or 3% hydrogen + 40% oxygen + 57% nitrogen (H group). Donor lungs were deflated in the control group and were harvested immediately after perfusion in the sham group (n = 10). Inflammation, oxidative stress, apoptosis, histological changes, mitochondrial energy metabolism, and mitochondrial structure and function were assessed. The expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) were also analyzed. Compared with the sham group, inflammatory response, oxidative stress, histopathological changes, and mitochondrial damage were severe in the other three groups. However, these injury indexes were remarkably decreased in O and H groups, with increased Nrf2 and HO-1 levels, elevated mitochondrial biosynthesis, inhibition of anaerobic glycolysis and restored mitochondrial structure and function compared with the control group. Moreover, inflation using hydrogen contributed to stronger protection against mitochondrial dysfunction and higher levels of Nrf2 and HO-1 when comparing with O group. Lung inflation using hydrogen during CIP may improve donor lung quality by mitigating mitochondrial structural anomalies, enhancing mitochondrial function, and alleviating oxidative stress, inflammation, and apoptosis, which may be achieved through activation of the Nrf2/HO-1 pathway.
Sections du résumé
BACKGROUND
BACKGROUND
Mitochondrial dysfunction results in poor organ quality, negatively affecting the outcomes of lung transplantation. Whether hydrogen benefits mitochondrial function in cold-preserved donors remain unclear. The present study assessed the effect of hydrogen on mitochondrial dysfunction in donor lung injury during cold ischemia phase (CIP) and explored the underlying regulatory mechanism.
METHODS
METHODS
Left donor lungs were inflated using 40% oxygen + 60% nitrogen (O group), or 3% hydrogen + 40% oxygen + 57% nitrogen (H group). Donor lungs were deflated in the control group and were harvested immediately after perfusion in the sham group (n = 10). Inflammation, oxidative stress, apoptosis, histological changes, mitochondrial energy metabolism, and mitochondrial structure and function were assessed. The expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) were also analyzed.
RESULTS
RESULTS
Compared with the sham group, inflammatory response, oxidative stress, histopathological changes, and mitochondrial damage were severe in the other three groups. However, these injury indexes were remarkably decreased in O and H groups, with increased Nrf2 and HO-1 levels, elevated mitochondrial biosynthesis, inhibition of anaerobic glycolysis and restored mitochondrial structure and function compared with the control group. Moreover, inflation using hydrogen contributed to stronger protection against mitochondrial dysfunction and higher levels of Nrf2 and HO-1 when comparing with O group.
CONCLUSIONS
CONCLUSIONS
Lung inflation using hydrogen during CIP may improve donor lung quality by mitigating mitochondrial structural anomalies, enhancing mitochondrial function, and alleviating oxidative stress, inflammation, and apoptosis, which may be achieved through activation of the Nrf2/HO-1 pathway.
Identifiants
pubmed: 37330482
doi: 10.1186/s12890-023-02504-6
pii: 10.1186/s12890-023-02504-6
pmc: PMC10276452
doi:
Substances chimiques
Hydrogen
7YNJ3PO35Z
NF-E2-Related Factor 2
0
Heme Oxygenase-1
EC 1.14.14.18
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213Subventions
Organisme : National Natural Science Foundation of China
ID : 81570088
Informations de copyright
© 2023. The Author(s).
Références
Front Physiol. 2021 Aug 02;12:699344
pubmed: 34408660
Biochem Pharmacol. 2020 Aug;178:114055
pubmed: 32470548
Lab Invest. 2019 Jun;99(6):793-806
pubmed: 30710119
Med Clin North Am. 2019 May;103(3):425-433
pubmed: 30955511
J Heart Lung Transplant. 2018 Oct;37(10):1271-1278
pubmed: 30100327
Mol Med Rep. 2016 Apr;13(4):3588-96
pubmed: 26936224
Physiol Rev. 1999 Oct;79(4):1127-55
pubmed: 10508231
Exp Mol Med. 2019 Jul 4;51(7):1-12
pubmed: 31273199
J Heart Lung Transplant. 2017 Oct;36(10):1047-1059
pubmed: 28784324
Transplantation. 2018 Aug;102(8):1253-1261
pubmed: 29762455
Br J Pharmacol. 2013 Jul;169(5):1035-47
pubmed: 23517027
Biomed Res Int. 2020 Jan 30;2020:1568209
pubmed: 32083123
Nat Med. 2007 Jun;13(6):688-94
pubmed: 17486089
Int Immunopharmacol. 2020 Jan;78:106049
pubmed: 31830624
Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L277-L288
pubmed: 32551862
Oxid Med Cell Longev. 2020 Sep 5;2020:8384742
pubmed: 32963703
Life Sci. 2021 May 1;272:119248
pubmed: 33621592
Acta Pharmacol Sin. 2005 Sep;26(9):1123-9
pubmed: 16115381
Toxicol Mech Methods. 2014 Dec;24(9):609-15
pubmed: 25258304
Transplantation. 2014 Sep 15;98(5):499-506
pubmed: 25121557
Am J Transplant. 2018 Jan;18 Suppl 1:434-463
pubmed: 29292599
J Heart Lung Transplant. 2021 Oct;40(10):1060-1072
pubmed: 34446355
Exp Biol Med (Maywood). 2021 Jun;246(12):1410-1418
pubmed: 33899545
Artif Organs. 2021 Jul;45(7):682-695
pubmed: 33349946
Am J Respir Crit Care Med. 1999 Aug;160(2):621-7
pubmed: 10430738
Microvasc Res. 2019 Sep;125:103885
pubmed: 31175855
Int Immunopharmacol. 2018 Dec;65:366-372
pubmed: 30380511
Cancer. 2000 Dec 15;89(12):2637-45
pubmed: 11135226
Life Sci. 2016 Apr 15;151:199-206
pubmed: 26969763
Int J Mol Sci. 2019 Jan 21;20(2):
pubmed: 30669692
Int Immunopharmacol. 2021 Dec;101(Pt B):108198
pubmed: 34634688
PLoS One. 2017 May 3;12(5):e0176992
pubmed: 28467497
Exp Biol Med (Maywood). 2015 Sep;240(9):1214-22
pubmed: 25662956
Pharmaceutics. 2021 Jan 22;13(2):
pubmed: 33499252
Anesth Analg. 2006 Jan;102(1):225-32
pubmed: 16368834
J Cell Sci. 2004 Nov 1;117(Pt 23):5479-87
pubmed: 15509864